- •Preface
- •Contents
- •1 Extracellular and Intracellular Signaling – a New Approach to Diseases and Treatments
- •1.1 Introduction
- •1.1.1 Linear Model of Drug Receptor Interactions
- •1.1.2 Matrix Model of Drug Receptor Interactions
- •1.2 Experimental Approaches to Disease Treatment
- •1.3 Adipokines and Disease Causation
- •1.4 Questions in Disease Treatment
- •1.5 Toxic Lifestyles and Disease Treatment
- •References
- •2.1 Introduction
- •2.2 Heterogeneity of Adipose Tissue Composition in Relation to Adipokine and Cytokine Secretion
- •2.3 Feedback between FA and the Adipocyte
- •2.6 Metabolic Programming of Autocrine Signaling in Adipose Tissue
- •2.8 Cell Heterogeneity in the Pancreatic Islet
- •2.16 Concluding Remarks
- •Acknowledgements
- •References
- •3 One Receptor for Multiple Pathways: Focus on Leptin Signaling
- •3.1 Leptin
- •3.2 Leptin Receptors
- •3.3 Leptin Receptor Signaling
- •3.3.4 AMPK
- •3.3.5 SOCS3
- •3.4 Leptin Receptor Interactions
- •3.4.1 Apolipoprotein D
- •3.4.2 Sorting Nexin Molecules
- •3.4.3 Diacylglycerol Kinase Zeta
- •3.4.4 Apolipoprotein J
- •References
- •4.1 Introduction
- •4.2 Leptin: A Brief Introduction
- •4.3 Expression of Leptin Receptors in Cardiovascular Tissues
- •4.6 Post Receptor Leptin Signaling
- •4.6.2 Mitogen Activated Protein Kinase Stimulation
- •4.7 Adiponectin
- •4.7.1 Adiponectin and Cardiovascular Disease
- •4.7.2 Adiponectin and Experimental Cardiac Hypertrophy
- •4.8 Resistin
- •4.8.1 Cardiac Actions of Resistin
- •4.8.1.1 Experimental Studies on the Cardiac Actions of Resistin
- •4.9 Apelin
- •4.9.1 Apelin and Heart Disease
- •4.10 Visfatin
- •4.11 Other Novel Adipokines
- •4.12 Summary, Conclusions and Future Directions
- •Acknowledgements
- •References
- •5 Regulation of Muscle Proteostasis via Extramuscular Signals
- •5.1 Basic Protein Synthesis
- •5.2.1 Hormones
- •5.2.1.1 Mechanisms of Action: Glucocorticoids
- •5.2.1.2 Mechanisms of Action: TH (T3)
- •5.2.1.3 Mechanisms of Action: Testosterone
- •5.2.1.4 Mechanisms of Action: Epinephrine
- •5.2.2 Local Factors (Autocrine/Paracrine)
- •5.2.2.1 Mechanisms of Action: Insulin/IGF Spliceoforms
- •5.2.2.2 Mechanisms of Action: Fibroblast Growth Factor (FGF)
- •5.2.2.3 Mechanisms of Action: Myostatin
- •5.2.2.4 Mechanisms of Action: Cytokines
- •5.2.2.5 Mechanisms of Action: Neurotrophins
- •5.2.2.7 Mechanisms of Action: Extracellular Matrix
- •5.2.2.8 Mechanisms of Action: Amino Acids (AA)
- •5.3 Regulation of Muscle Proteostasis in Humans
- •5.3.1 Nutrients as Regulators of Muscle Proteostasis in Man
- •5.3.2 Muscular Activity (i.e. Exercise) as a Regulator of Muscle Proteostasis
- •5.4 Conditions Associated with Alterations in Muscle Proteostasis in Humans
- •5.4.2 Disuse Atrophy
- •5.4.3 Sepsis
- •5.4.4 Burns
- •5.4.5 Cancer Cachexia
- •References
- •6 Contact Normalization: Mechanisms and Pathways to Biomarkers and Chemotherapeutic Targets
- •6.1 Introduction
- •6.2 Contact Normalization
- •6.3 Cadherins
- •6.4 Gap Junctions
- •6.5 Contact Normalization and Tumor Suppressors
- •6.6 Contact Normalization and Tumor Promoters
- •6.7 Conclusions
- •References
- •7.1 Introduction
- •7.2 Background on Migraine Headache
- •7.3 Migraine and Neuropathic Pain
- •7.4 Role of Astrocytes in Pain
- •7.5 Adipokines and Related Extracellular Signalling
- •7.6 The Future of Signaling Research to Migraine
- •Acknowledgements
- •References
- •8.1 Alzheimer’s Disease
- •8.1.2 Target for AD Therapy
- •8.2 AD and Metabolic Dysfunction
- •8.2.1 Impaired Glucose Metabolism
- •8.2.2 Lipid Disorders
- •8.2.3 Obesity
- •8.3 Adipokines
- •8.3.1 Leptin
- •8.3.2 Adiponectin
- •8.3.3 Resistin
- •8.3.4 Visfatin
- •8.3.5 Plasminogen Activator Inhibitor
- •8.3.6 Interleukin-6
- •8.4 Conclusions
- •References
- •9.1 Introduction
- •9.1.1 Structure and Function of Astrocytes
- •9.1.1.1 Morphology
- •9.1.1.2 Astrocyte Functions
- •9.1.2 Responses of Astrocytes to Injury
- •9.1.2.1 Reactive Astrocytosis
- •9.1.2.2 Cell Swelling
- •9.1.2.3 Alzheimer Type II Astrocytosis
- •9.2 Intracellular Signaling System in Reactive Astrocytes
- •9.2.1 Oxidative/Nitrosative Stress (ONS)
- •9.2.2 Protein Kinase C (PKC)
- •9.2.5 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3 Signaling Systems in Astrocyte Swelling
- •9.3.1 Oxidative/Nitrosative Stress (ONS)
- •9.3.2 Cytokines
- •9.3.3 Protein Kinase C (PKC)
- •9.3.5 Protein Kinase G (PKG)
- •9.3.7 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3.10 Ion Channels/Transporters/Exchangers
- •9.4 Conclusions and Perspectives
- •Acknowledgements
- •References
- •10.1 Adipokines, Toxic Lipids and the Aging Brain
- •10.1.1 Toxic Lifestyles, Adipokines and Toxic Lipids
- •10.1.2 Ceramide Toxicity in the Brain
- •10.3 Oxygen Radicals, Hydrogen Peroxide and Cell Death
- •10.4 Gene Transcription and DNA Damage
- •10.5 Conclusions
- •References
- •11.1 Introduction
- •11.2 Cellular Signaling
- •11.2.1 Types of Signaling
- •11.2.2 Membrane Proteins in Signaling
- •11.3 G Protein-Coupled Receptors
- •11.3.1 Structure of GPCRs
- •11.3.1.1 Structure Determination
- •11.3.1.2 Structural Diversity of Current GPCR Structures
- •11.3.1.3 Prediction of GPCR Structure and Ligand Binding
- •11.3.2 GPCR Activation: Conformation Driven Functional Selectivity
- •11.3.2.2 Ligand or Mutation Stabilized Ensemble of GPCR Conformations
- •11.3.2.4 GPCR Dimers and Interaction with Other Proteins
- •11.3.3 Functional Control of GPCRs by Ligands
- •11.3.3.1 Biased Agonism
- •11.3.3.2 Allosteric Ligands and Signal Modulation
- •11.3.4 Challenges in GPCR Targeted Drug Design
- •11.4 Summary and Looking Ahead
- •Acknowledgements
- •References
- •12.1 Introduction
- •12.5.1 Anthocyanins
- •12.5.2 Gallates
- •12.5.3 Quercetin
- •12.5.5 Piperine
- •12.5.6 Gingerol
- •12.5.7 Curcumin
- •12.5.8 Guggulsterone
- •12.6.1 Phytanic Acid
- •12.6.2 Dehydroabietic Acid
- •12.6.3 Geraniol
- •12.7 Agonists of LXR that Reciprocally Inhibit NF-jB
- •12.7.1 Stigmasterol
- •12.7.3 Ergosterol
- •12.8 Conclusion
- •References
- •13.1 Introduction
- •13.2 Selective Dopaminergic Neuronal Death
- •13.3 Signaling Pathways Involved in Selective Dopaminergic Neuronal Death
- •13.3.1 Initiators and Signaling Molecules
- •13.3.1.1 Response to Oxidative and Nitrosative Stress
- •13.3.1.2 Response to Altered Proteostasis
- •13.3.1.3 Response to Glutamate
- •13.3.1.4 Other Initiators
- •13.3.2 Signal Transducers, Intracellular Messengers and Upstream Elements
- •13.3.2.2 Small GTPases
- •13.3.3 Intracellular Signaling Cascades
- •13.3.3.1 Mitogen Activated Protein Kinases (MAPK) Pathway
- •13.3.3.2 PI3K/Akt Pathway
- •13.3.3.4 Unfolded Protein Response (UPR)
- •13.3.4 Potentially Involved Intracellular Signaling Components
- •13.3.4.3 PINK1
- •13.3.5.2 Dopamine Metabolism
- •13.3.5.3 Cell Cycle
- •13.3.5.4 Autophagy
- •13.3.5.5 Apoptosis
- •13.4 Conclusions
- •References
- •Subject Index
Phytochemicals as Modulators of Signaling in Inflammation |
243 |
12.7.2b-Sitosterol
b-sitosterol is another plant-derived sterol found in black cumin seed, pecans, saw palmetto, avocados, pumpkin seed, cashew, rice brain, corn oil and soybeans. It is considered to be a potent LXR agonist and anti-inflammatory agent49 (Figure 12.14). In cell culture models of osteoarthritis, b-sitosterol was able to decrease proinflammatory pathways.
12.7.3Ergosterol
Ergosterol is another LXR agonist, found in fungal membranes, and is considered to be a very potent LXR agonist. In fact, some of the ergosterol derivatives found in nature activate LXR (Figure 12.15) much more e ectively than the known cholesterol agonists.50 Ergosterol has been found to have antiinflammatory properties as well.51
12.8 Conclusion
Numerous phytochemicals and natural products can intervene in signal transduction mechanisms to attenuate NF-kB-mediated inflammatory
H
H
H H
HO
Figure 12.14 b-Sitosterol.
H
H H
HO
Figure 12.15 Ergosterol.
244 |
Chapter 12 |
pathways. However, much remains to be elucidated regarding the pharmacology, toxicology and peak concentrations of these natural products that can be achieved in human plasma. Transcriptional regulators in inflammation present a powerful strategy to target chronic inflammatory diseases. It may be that the life-long prophylactic use of these natural ligands may preempt the use of stronger synthetic derivatives later on.
References
1.C. Garcia and J. Adams, Healing with Medicinal Plants of the West – Cultural and Scientific Basis for Their Use, Abedus Press, La Crescenta, 2005.
2.A. Rogerio, A. Sa´-Nunes and L. Faccioli, Pharmacol. Res., 2010, 62, 298.
3.B. Aggarwal, H. Ichikawa, P. Garodia, P. Weerasinghe, G. Sethi, I. Bhatt,
M.Pandey, S. Shishodia and M. Nair, Expert Opin. Ther. Targets, 2006, 10, 87.
4.R. Talhouk, C. Karam, S. Fostok, W. El-Jouni and E. Barbour, J. Med. Food, 2007, 10, 1.
5.H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G. Cole, N. Cooper,
P.Eikelenboom, M. Emmerling, B. Fiebich, C. Finch, S. Frautschy,
W.Gri n, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I. Mackenzie,
P.McGeer, M. O’Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman,
J.Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk and T. Wyss-Coray, Neurobiol. Aging, 2000, 21, 383.
6.A. Castrillo and P. Tontonoz, Ann. Rev. Cell Dev. Biol., 2004, 20, 455.
7.S. Joseph, A. Castrillo, B. La tte, D. Mangelsdorf and P. Tontonoz, Nat.
Med., 2003, 9, 213.
8. S. Sueyoshi, M. Mitsumata, Y. Kusumi, M. Niihashi, M. Esumi,
T.Yamada and I. Sakurai, Pathol. Res. Pract., 2010, 206, 429.
9.M. Hamblin, L. Chang, Y. Fan, J. Zhang and Y. Chen, Antioxid. Redox Signal., 2009, 11, 1415.
10.R. Touyz and E. Schi rin, Vascul. Pharmacol., 2006, 45, 19.
11.J. Fruchart, P. Duriez and B. Staels, Curr. Opin. Lipidol., 1999, 10, 245.
12.H. Takano and I. Komuro, Circ. J., 2009, 73, 214.
13.H. Takano and I. Komuro, J. Diab. Complications, 2002, 16, 108.
14.E. Mannucci and M. Monami, Curr. Diab. Rep., 2009, 9, 342.
15.F. Martens, F. Visseren, J. Lemay, E. de Koning and T. Rabelink, Drugs, 2002, 62, 1463.
16.N. Zelcer, N. Khanlou, Q. Clare, R. Jiang, E. Reed-Geaghan, G. Landreth,
H.Vinters and P. Tontonoz, Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 10601.
17.G. Landreth, Exp. Neurol., 2006, 199, 245.
18.G. Landreth, Q. Jiang, S. Mandrekar and M. Heneka, Neurother., 2008, 5, 481.
Phytochemicals as Modulators of Signaling in Inflammation |
245 |
19.Q. Jiang, M. Heneka and G. Landreth, CNS Drugs, 2008, 22, 1.
20.Z. Israili, Am. J. Ther., 2009, 17, 284.
21.Z. Rasheed, N. Akhtar, A. Anbazhagan, S. Ramamurthy, M. Shukla and
T.Haqqi, J. Inflamm. (Lond.), 2009, 8, 6.
22.M. Rettig, D. Heber, J. An, N. Seeram, J. Rao, H. Liu, T. Klatte,
A.Belldegrun, A. Moro, S. Henning, D. Mo, W. Aronson and A. Pantuck,
Mol. Cancer Ther., 2008, 7, 2662.
23.P. Milbury, J. Vita and J. Blumberg, J. Nutr., 2010, 140, 1099.
24.T. Murase, N. Kume, T. Hase, Y. Shibuya, Y. Nishizawa, I. Tokimitsu and
T.Kita, Arterioscler. Thromb. Vasc. Biol., 1999, 19, 1412.
25.W. Loke, J. Jenner, M. Proudfoot, A. McKinley, J. Hodgson, B. Halliwell and K. Croft, J. Nutr., 2009, 139, 2309.
26.K. Natarajan, S. Manna, M. Chaturvedi and B. Aggarwal, Arch. Biochem. Biophys., 1998, 352, 59.
27.G. Peet and J. Li, J. Biol. Chem., 1999, 274, 32655.
28.S. Egert, S. Wol ram, A. Bosy-Westphal, C. Boesch-Saadatmandi,
A.Wagner, J. Frank, G. Rimbach and M. Mueller, J. Nutr., 2008, 138, 1615.
29.C. Gardner, L. Chatterjee and A. Franke, J. Nutr. Biochem., 2009, 20, 227.
30.S. Kumar, V. Singhal, R. Roshan, A. Sharma, G. Rembhotkar and
B.Ghosh, Eur. J. Pharmacol., 2007, 575, 177.
31. M. Kakarala, S. Dubey, M. Tarnowski, C. Cheng, S. Liyanage,
T.Strawder, K. Tazi, A. Sen, Z. Djuric and D. Brenner, J. Ag. Food. Chem., 2010, 58, 6594.
32.Y. Lee, K. Lee, S. Chen and H. Chang, Biochem. Biophys. Res. Commun., 2009, 382, 134.
33.W. Wang, C. Li, X. Wen, P. Li and L. Qi, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877, 671.
34.H. Youn, S. Saitoh, K. Miyake and D. Hwang, Biochem. Pharmacol., 2006, 72, 62.
35.A. Kunnumakkara, P. Anand and B. Aggarwal, Cancer Lett., 2008, 269, 199.
36.S. Aggarwal, H. Ichikawa, Y. Takada, S. Sandur, S. Shishodia and
B.Aggarwal, Mol. Pharmacol., 2006, 69, 195.
37.P. Anand, A. Kunnumakkara, R. Newman and B. Aggarwal, Mol. Pharm., 2007, 4, 807.
38.H. Ichikawa and B. Aggarwal, Clin. Cancer Res., 2006, 12, 662.
39.Y. Lee, J. Lee, E. Noh, E. Kim, M. Song, W. Jung, S. Park, J. Kim, J. Park,
K.Kwon and B. Park, Life Sci., 2008, 82, 1203.
40.R. Deng, Cardiovasc. Drug Rev., 2007, 25, 375.
41.T. Goto, N. Takahashi, S. Hirai and T. Kawada, PPAR Res., 2010, 2010, 483958.
42.M. Heim, J. Johnson, F. Boess, I. Bendik, P. Weber, W. Hunziker and
B.Fluhmann, FASEB J., 2002, 16, 718.
43.J. Avigan, Biochim. Biophys. Acta, 1966, 116, 391.
44.M. Kang, S. Hirai, T. Goto, K. Kuroyanagi, Y. Lee, T. Uemura, Y. Ezaki,
N.Takahashi and T. Kawada, Biochem. Biophys. Res. Commun., 2008, 369, 333.
246 |
Chapter 12 |
45.N. Takahashi, T. Kawada, T. Goto, T. Yamamoto, A. Taimatsu,
N.Matsui, K. Kimura, M. Saito, M. Hosokawa, K. Miyashita and T. Fushiki, FEBS Lett., 2002, 514, 315.
46.Y. Su, S. Chao, M. Lee, T. Ou and Y. Tsai, Planta Med., 2010, 109, 524.
47.C. Yang, J. McDonald, A. Patel, Y. Zhang, M. Umetani, F. Xu,
E.Westover, D. Covey. D. Mangelsdorf, J. Cohen and H. Hobbs, J. Biol. Chem., 2006, 281, 27816.
48.O. Gabay, C. Sanchez, C. Salvat, F. Chevy, M. Breton, G. Nourissat,
C.Wolf, C. Jacques and F. Berenbaum, Osteoarthritis Cartilage, 2010, 18, 106.
49.J. Yuk, J. Woo, C. Yun, J. Lee, J. Kim, G. Song, E. Yang, I. Hur and
I.Kim, Int. Immunopharmacol., 2007, 7, 1517.
50.E. Kaneko, M. Matsuda, Y. Yamada, Y. Tachibana, I. Shimomura and
M.Makishima, J. Biol. Chem., 2003, 278, 36091.
51.N. Kageyama-Yahara, P. Wang, X. Wang, T. Yamamoto and M. Kadowaki,
Biol. Pharm. Bull., 2010, 33, 142.